Chest
Clinical Investigations: AsthmaShort-term Growth in Asthmatic Children Using Fluticasone Propionate
Section snippets
Materials and Methods
The present study was undertaken during the baseline period of an ongoing long-term clinical trial on effects and side effects of two different treatment schedules of FP. The baseline period of this trial consisted of a 6-week run-in period during which patients inhaled FP from a dry-powder inhaler (Diskhalerinhaler; Glaxo Wellcome; Greenford, UK) at a dose of 100 μg twice daily, followed by a 2-week washout period during which patients used no inhaled corticosteroids or other anti-inflammatory
Results
Twenty-one patients completed the study. Clinical characteristics are shown in Table 1. Figure 1 shows the lower leg growth velocity during 6 weeks of treatment with inhaled corticosteroids (run-in phase) and during 2 weeks without inhaled corticosteroids (washout phase). Because there was no difference in left and right lower leg growth velocity, the mean of both legs was used.
Blister counts showed mean (SD) compliance with prescribed dosages of 94% (9%). There were no significant differences
Discussion
In this study, we did not find a (significant) reduction in lower leg growth velocity in asthmatic children during treatment with FP, 100 μg bid, via dry-powder inhaler as compared with treatment with only an inhaled β2-agonist on demand. In fact, the observed trend (Fig 1) was that lower leg growth velocity tended to increase during treatment with FP. Thus, it is highly unlikely that our results can be explained by insufficient power to detect a growthsuppressing effect of FP on short-term
References (10)
Normal growth and techniques of growth assessment
Clin Endocrinol Metab
(1986)- et al.
A meta-analysis of the effect of oral and inhaled corticosteroids on growth
J Allergy Clin Immunol
(1994) Long-, intermediate- and short-term growth studies in asthmatic children treated with inhaled glucocorticosteroids
Eur Respir J
(1996)- et al.
Growth of asthmatic children during treatment with budesonide: a double blind trial
BMJ
(1991) - et al.
Controlled study of linear growth in asthmatic children during treatment with inhaled glucocorticosteroids
Pediatrics
(1992)
Cited by (32)
Inhaled corticosteroids in asthma: Which tolerance in 2009?
2010, Archives de PediatrieEffect on growth of long-term treatment with intranasal triamcinolone acetonide aqueous in children with allergic rhinitis
2008, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :Although published guidelines recommend primary INS treatment for patients with AR,1,4,5 there remain concerns that this treatment may cause growth suppression in children and adolescents. In that regard, there is a large body of studies18–23 that support growth suppression in some patients treated with inhaled corticosteroids (ICSs) for asthma or INSs for AR, but much of that work focuses on short-term growth effects as measured by means of knemometry. Long-term treatment studies report conflicting results.19,24–31
Safety of inhaled corticosteroids: Room for improvement
2007, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :A third double-blind study in 40 children with asthma, ages 1–3 years, indicated that both FP and budesonide caused a significant slowing of lower-leg growth compared with placebo [41]. Although these studies indicate a decrease in growth velocity in the short term and reflect systemic effects of ICS, other studies suggest that ICS have no significant effect on long-term growth [42]. Some surveys have demonstrated no negative effect of ICS on attainment of adult height.
Adverse events of inhaled steroids in childhood
2004, Archives de PediatrieSafety of inhaled corticosteroid therapy in young children with asthma
2001, Annals of Allergy, Asthma and Immunology
This study was supported by Glaxo Wellcome, the Netherlands.